普萘洛尔治疗增生期血管瘤患儿血清中血管内皮生长因子及基质金属蛋白酶-9的变化

目的 研究普萘洛尔口服治疗增生期血管瘤,及对血清中血管内皮生长因子（vascular endothelial growth factor,VEGF）、基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)水平的影响。方法 采用ELISA法检测患者服药4、8周后血清VEGF、MMP-9水平,并分析其与预后的关系。结果 治疗前血清VEGF水平最高,而服药后4周(255.7±130.4)和服药后8周(224.2±120.6)VEGF水平呈逐渐下降趋势,治疗后8周VEGF水平显著低于治疗前(P＜0.05)。MMP-9的表达变化与VEGF一致,并与VEGF呈正相关。结论 普萘洛尔可以通过降低患者血清VEGF和MMP-9水平,从而治疗增生期血管瘤。

The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol

Objective To study the level of serum vascular endothelial growth factor, matrix metalloproteinases-9 in the proliferative hemangioma before and after propranolol treatment. Methods The serum VEGF, MMP-9 was detected with ELISA assay before treatment and after 4 weeks and 8 weeks of propranolol treatment. The relationship between the serum VEGF, MMP-9 and the prognosis was analyzed. Results The serum VEGF(295.4 ± 158.1 ) pg/ml was high before treatment, then decreased after 4 weeks and 8 weeks of treatment (255.7 ± 130.4) pg/ml, (224.2 ± 120.6) pg/ml. The serum VEGF was significantly lower after 8 weeks of treatment( P ＜ 0.05 ). The serum MMP-9 was also decreased after treatment, showing a positive relationship with VEGF. Conclusions Propranolol can treat the proliferative hemangioma through decreasing the serum VEGF and MMP-9.